Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
69.13
+5.98 (+9.47%)
Streaming Delayed Price
Updated: 1:18 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
February 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
February 27, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
February 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
February 12, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
February 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
February 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
February 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
February 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
January 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Amended Collaboration and Equity Investment
January 29, 2024
From
Arcus Biosciences
Via
Business Wire
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Courts Find Gilead "Morally Blameworthy" for Withholding HIV Medication
January 23, 2024
January 23, 2024 -- California's Court of Appeals denies Gilead Sciences' request for immunity from liability
Via
24-7 Press Release
Gilead Provides Update on Phase 3 EVOKE-01 Study
January 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Will the Biotech sector sustain its momentum in 2024?
January 04, 2024
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.
Via
MarketBeat
Topics
ETFs
Gilead Sciences to Present at Upcoming Investor Conference
December 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
December 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
December 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.